Elevance Health Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $201.1B+13.6% YoYTTM through 30 Jun 2026
Net Income $5B-17.0% YoYTTM through 30 Jun 2026
Free Cash Flow $6.3BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | 3.5% |
| Operating Margin | 2.7% |
| Net Margin | 2.5% |
Returns
11.1%ROE
3.9%ROA
7.6%ROIC
Balance Sheet Health
Debt / Equity0.69x
Current Ratio1.52x
Net Debt$20.8B
Cash & Equivalents$10.2B
Quality Metrics
Altman Z-Score3.00
Piotroski F-Score7 / 9
FCF Margin3.1%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $199.1B
Diluted EPS$22.61TTMFY2025: $25.21
Dividend
$3.44Per share, FY20260.85%Yield-5.3%5-yr growth
Capital Allocation
Capex Intensity0.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Health Benefits | $42.5B | +3.0% | View detailsMedicare Advantage performance is stronger than expected, with disciplined plan design and favorable claims experience supporting a path to at least a 2% operating margin in 2026. |
| Carelon | $18B | +7.9% | View detailsReflects improved profitability in specialty pharmacy and continued expansion of risk-based capabilities. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.